ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy

Tu, Hai-Yan; Yin, Kai; Zhao, Xiaotian; Ke, E-E; Wu, Si-Pei; Li, Yang-Si; Zheng, Mei-Mei; Liu, Si-Yang Maggie; Xu, Chong-Rui; Sun, Yue-Li; Lin, Jia-Xin; Bai, Xiao-Yan; Zhang, Yi-Chen; Zhou, Qing; Yang, Jin-Ji; Zhong, Wen-Zhao; Wang, Bing-Chao; Zhang, Xu-Chao; Zhu, Dongqin; Yang, Lingling; Ou, Qiuxiang; Wu, Yi-Long*广东省人民医院; 南方医科大学; 1
Molecular Oncology2023-8DOI: 10.1002/1878-0261.13439
1被引5阅读
引用收藏
分享

摘要

The efficacy of immunotherapy in advanced HER2-mutated non-small-cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)-based therapy efficacy between patients with ex20ins and non-ex20ins. Two external cohorts (TCGA, n = 21; META-ICI, n = 30) were used for validation. In the GLCI cohort, 68.2% of patients displayed programmed death-ligand 1 (PD-L1) expression < 1%. Compared with ex20ins patients, non-ex20ins patients had more concurrent mutations in the GLCI cohort (P < 0.01) and a higher tumour mutation burden in the TCGA cohort (P = 0.03). Under ICI-based therapy, advanced NSCLC patients with non-ex20ins had potentially superior progression-free survival [median: 13.0 vs. 3.6 months, adjusted hazard ratio (HR): 0.31, 95% confidence interval (CI): 0.11-0.83] and overall survival (median: 27.5 vs. 8.1 months, adjusted HR: 0.39, 95% CI: 0.13-1.18) to ex20ins patients, consistent with findings in the META-ICI cohort. ICI-based therapy may serve as an option for advanced HER2-mutated NSCLC, with potentially better efficacy in non-ex20ins patients. Further investigations are warranted in clinical practice.

学科与关键词

关键词
advanced NSCLCexon 20 insertionhuman epidermal growth factor receptor 2immune checkpoint inhibitornon-exon 20 insertion
相关
加载中…
  • Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions
    Tu, Hai-Yan; Kai Yin; Ke, E-E; Wu, Si-Pei; Zhao, Xiaotian; Li, Yang-Si; Zheng, Mei-Mei; Liu, Si-Yang Maggie; Sun, Yue-Li; Lin, Jia-Xin; Bai, Xiao-Yan; Zhang, Yi-Chen; Qing Zhou; Yang, Jin-Ji; Zhong, Wenzhao; Wang, Bin-Chao; Zhu, Dongqin; Yang, Lingling; Ou, Qiuxiang; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Zhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
  • First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
    Liu, Si-Yang Maggie; Tu, Hai-Yan; Wei, Xue-Wu; Yan, Hong-Hong; Dong, Xiao-Rong; Cui, Jiu-Wei; Zhou, Zhen; Xu, Chong-Rui; Zheng, Ming-Ying; Li, Yang-Si; Wang, Zhen; Bai, Xiao-Yan; Li, An-Na; Sun, Yue-Li; Huang, Jie; Lin, Jia-Xin; Ke, E. E.; Xu, Bing-Fei; Lu, Chang; Du, Yingying; Chen, Yuan; Ma, Rui; Wang, Bu-Hai; Cang, Shun-Dong; Wang, Bin-Chao; Chen, Hua-Jun; Yang, Jin-Ji; Li, Yangqiu*; Zhou, Qing*; Wu, Yi-Long*Nature Medicine, 2023, 29(8): 2079-+.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Oncology
发表日期
2023-08
卷期
第 17 卷, 第 8 期
页码
1581-1594
DOI
10.1002/1878-0261.13439
语言
ENGLISH
成果收录
SCIE
资助标注
Key Lab System Project of Guangdong Science and Technology Department-Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; GDPH Scientific Research Funds for Leading Medical Talents in Guangdong Province [KJ012019426]; Beijing Health Alliance Charitable Foundation [TB219010]

作者

  • T

    Tu, Hai-Yan (第一作者)

    guangdong prov peoples hosp · southern med univ

  • Y

    Yin, Kai

    guangdong prov peoples hosp · southern med univ · 2

查看全部 22 位作者收起作者
  • Z

    Zhao, Xiaotian

  • K

    Ke, E-E

    guangdong prov peoples hosp · southern med univ

  • W

    Wu, Si-Pei

    guangdong prov peoples hosp

  • L

    Li, Yang-Si

    guangdong prov peoples hosp · southern med univ

  • Z

    Zheng, Mei-Mei

    guangdong prov peoples hosp · southern med univ

  • L

    Liu, Si-Yang Maggie

    1

  • X

    Xu, Chong-Rui

    guangdong prov peoples hosp · southern med univ

  • S

    Sun, Yue-Li

    guangdong prov peoples hosp · southern med univ

  • L

    Lin, Jia-Xin

    guangdong prov peoples hosp · southern med univ

  • B

    Bai, Xiao-Yan

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhang, Yi-Chen

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhou, Qing

    guangdong prov peoples hosp · southern med univ

  • Y

    Yang, Jin-Ji

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhong, Wen-Zhao

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Bing-Chao

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhang, Xu-Chao

    guangdong prov peoples hosp · 2 · southern med univ

  • Z

    Zhu, Dongqin

  • Y

    Yang, Lingling

  • O

    Ou, Qiuxiang

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp · southern med univ · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417